What is Accellix?
Accellix is a biotechnology company dedicated to developing and commercializing the Accellix Platform. This innovative solution enables customers in the cell and gene therapy sector to meet stringent quality control (QC) requirements as they advance life-changing therapies for patients worldwide. The Accellix platform facilitates the migration of existing cell assays, offering a benchtop flow cytometer that operates with capillary cartridges integrated with dry reagents. This technology provides unmatched reproducibility and ease of use for automated multi-parametric cell analysis, positioning Accellix as a key enabler in the biopharmaceutical industry.
How much funding has Accellix raised?
Accellix has raised a total of $19.6M across 3 funding rounds:
Debt
$150K
Series D
$9.5M
Private Equity
$10M
Debt (2020): $150K with participation from PPP
Series D (2020): $9.5M led by bioMérieux SA
Private Equity (2021): $10M supported by BroadOak Capital Partners
Key Investors in Accellix
BroadOak Capital Partners
BroadOak Capital Partners is a boutique financial institution specializing in direct investment and banking services for life sciences and biopharma services companies. Since its inception in 2006, it has invested in over 70 companies and advised on more than 50 successful M&A transactions. The firm focuses on life sciences tools, diagnostics, and biopharma services, leveraging its in-house expertise and extensive networks to deliver exceptional results for its clients. BroadOak aims to provide growth capital and advisory services to help management teams optimize their business strategies.
bioMérieux SA
bioMérieux SA is a global leader in the field of in vitro diagnostics, providing a broad range of diagnostic solutions designed to improve patient health and ensure consumer safety. The company's expertise spans infectious diseases, microbiology, and industrial microbiology, with a strong commitment to innovation and scientific advancement. Their investment in Accellix suggests a strategic interest in complementary technologies that enhance cell and gene therapy development and quality control.
PPP
Public-Private Partnership
What's next for Accellix?
With a substantial enterprise-level funding round and a recent strategic investment, Accellix is poised for accelerated growth and market penetration. The company's focus on enabling critical QC requirements for cell and gene therapies aligns with a significant and expanding market need. Future strategic initiatives will likely involve scaling production of the Accellix Platform, expanding its customer base within the biopharmaceutical and research sectors, and potentially forging new partnerships to further integrate its technology into the therapeutic development pipeline. Continued investment in R&D to enhance platform capabilities and broaden assay compatibility will be crucial for maintaining its competitive edge.
See full Accellix company page
